Evandro de Azambuja, Director of Membership 2023-2025 at ESMO – European Society for Medical Oncology, shared on LinkedIn:
“Overall Survival benefit with adjuvant trastuzumab and pertuzumab in Aphinity (node positive with absolute benefit of 2.7%)! All those years of hard work are translating into improved patients outcomes!”
Read this article about Breast Cancer on OncoDaily.
